- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05377320
Patientlighed for beslutningstagning i forebyggelse af kardiovaskulær toksicitet (PACT): En gennemførlighedsundersøgelse
This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
For this feasibility study, the researchers will create the clinical decision aid and test the central hypothesis that this novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists and will favorably impact appropriate medication use and cardiac imaging surveillance. The hypothesis is supported by preliminary data suggesting that an initial and rudimentary version of the clinical aid increases appropriate medication use and imaging follow-up in cardio-oncology patients. Success will be determined by ≥85% of clinic visits using the clinical decision aid resulting in pursuit of medication use and cardiac imaging surveillance patterns commensurate with recommendations specific to cancer survivors, with overall rates the same or higher than the group without the clinical decision aid, as well as overall favorable patient and physician focus group comments and survey responses.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Yee Chung Cheng, MD
- Telefonnummer: 414-805-4600
- E-mail: ycheng@mcw.edu
Studiesteder
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Froedtert & the Medical College of Wisconsin
-
Ledende efterforsker:
- Yee Chung Chen, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Cancer survivors at intermediate, high, or very high risk for developing cardiovascular disease will pursue a cardio-oncology visit.
Beskrivelse
Inclusion Criteria:
- Patients ≥18 years with a history of cancer.
- Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis.
- Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction.
- Ability to understand a written informed consent form, and willing to sign it prior to study registration.
Exclusion Criteria:
- Patient <18 years.
- Without a personal history of cancer.
- Existing cardiomyopathy diagnosed after cancer diagnosis.
- Documented cognitive impairment.
- Patient or patient representative who is unable and unwilling to sign the informed consent form.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Clinical Decision Aid Group
In this group, physicians will use standard care plus the clinical decision aid. |
The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24. |
|
Control Group
In this group, physicians will use standard care only. |
Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Medication use
Tidsramme: Week 0
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 0
|
|
Medication use
Tidsramme: Week 12
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 12
|
|
Medication use
Tidsramme: Week 24
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 24
|
|
Imaging surveillance
Tidsramme: Week 0
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 0
|
|
Imaging surveillance
Tidsramme: Week 12
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 12
|
|
Imaging surveillance
Tidsramme: Week 24
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 24
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Yee Chung Cheng, MD, Medical College of Wisconsin
Publikationer og nyttige links
Generelle publikationer
- Brown SA, Chung BY, Doshi K, Hamid A, Pederson E, Maddula R, Hanna A, Choudhuri I, Sparapani R, Bagheri Mohamadi Pour M, Zhang J, Kothari AN, Collier P, Caraballo P, Noseworthy P, Arruda-Olson A; Cardio-Oncology Artificial Intelligence Informatics and Precision Equity (CAIPE) Research Team Investigators. Patient similarity and other artificial intelligence machine learning algorithms in clinical decision aid for shared decision-making in the Prevention of Cardiovascular Toxicity (PACT): a feasibility trial design. Cardiooncology. 2023 Jan 23;9(1):7. doi: 10.1186/s40959-022-00151-0.
- Brown SA, Hamid A, Pederson E, Bs AH, Maddula R, Goodman R, Lamberg M, Caraballo P, Noseworthy P, Lukan O, Echefu G, Berman G, Choudhuri I; Cardio-Oncology Artificial Intelligence Informatics & Precision Equity (CAIPE) and Patient Similarity Algorithms in the Prevention of Cardiovascular Toxicity (PACT) Research Team Investigators. Simplified rules-based tool to facilitate the application of up-to-date management recommendations in cardio-oncology. Cardiooncology. 2023 Oct 27;9(1):37. doi: 10.1186/s40959-023-00179-w.
- Brown SA, Fang MZ, Sparapani R, Zhou Y, Osinski K, Taylor B, Yu D, Blessing J, Shah R, Collier P, BagheriMohamadiPour M, Zhang J, Kothari A, Echefu G, Rickards J, Otto C, Sanchez Z, Olson J, Arruda-Olson A, Cheng YC, Cheng F; Cardio-Oncology Artificial Intelligence Informatics and Precision Equity, and Patient Similarity Algorithms in the Prevention of Cardiovascular Toxicity Research Team Investigators. PrevCardioOncAI: Machine Learning Algorithms for Predicting Cardiovascular Disease in Cancer Survivors. J Am Heart Assoc. 2025 Dec 16;14(24):e030363. doi: 10.1161/JAHA.123.030363. Epub 2025 Dec 11.
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Karsygdomme
- Hjerte-kar-sygdomme
- Sår og skader
- Patologiske processer
- Hjertesygdomme
- Metaboliske sygdomme
- Glukosemetabolismeforstyrrelser
- Kemisk inducerede lidelser
- Lægemiddelrelaterede bivirkninger og uønskede reaktioner
- Strålingsskader
- Åreforkalkning
- Åreforkalkning
- Arterielle okklusive sygdomme
- Perifere vaskulære sygdomme
- Koronar sygdom
- Myokardieiskæmi
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Neoplasmer
- Hjertefejl
- Forhøjet blodtryk
- Iskæmi
- Diabetes mellitus
- Kardiomyopatier
- Perifer arteriel sygdom
- Koronararteriesygdom
- Kardiotoksicitet
- Sundhedstjenester Administration
- Sundhedsvæsenets kvalitet, adgang og evaluering
- Sundhedskvalitet
- Kvalitetsindikatorer, sundhedsvæsenet
- Standard for pleje
Andre undersøgelses-id-numre
- PRO00039290
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .